SBT-259

SBT-259 is an investigational mitochondria-targeted peptide therapeutic being developed by Stealth BioTherapeutics for rare peripheral neuropathies, including Charcot-Marie-Tooth disease. Public company materials describe it as part of Stealth's pipeline of compounds aimed at correcting mitochondrial dysfunction. Detailed public disclosure of its exact molecular sequence, formal biological target, route, and dosage form appears limited; based on Stealth's broader platform, it is best characterized as an early-stage peptide biologic intended to improve mitochondrial function in neuropathic disease settings where mitochondrial impairment is believed to contribute to pathology.